What is HC Wainwright’s Forecast for CRBP Q1 Earnings?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Free Report) – Research analysts at HC Wainwright issued their Q1 2027 EPS estimates for Corbus Pharmaceuticals in a note issued to investors on Tuesday, November 10th. HC Wainwright analyst A. Maldonado forecasts that the biopharmaceutical company will post earnings of ($1.58) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($6.33) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals’ Q2 2027 earnings at ($1.52) EPS, Q3 2027 earnings at ($1.52) EPS and Q4 2027 earnings at ($1.52) EPS.

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) last announced its earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.54).

Other research analysts have also issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research note on Thursday, October 15th. Oppenheimer reaffirmed an “outperform” rating on shares of Corbus Pharmaceuticals in a research report on Wednesday. Mizuho dropped their target price on Corbus Pharmaceuticals from $24.00 to $23.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, Wall Street Zen downgraded Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $35.67.

Get Our Latest Analysis on CRBP

Corbus Pharmaceuticals Stock Down 14.7%

CRBP stock opened at $3.41 on Wednesday. The company has a 50 day moving average price of $5.83 and a two-hundred day moving average price of $8.37. Corbus Pharmaceuticals has a one year low of $2.81 and a one year high of $12.88.

Hedge Funds Weigh In On Corbus Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Orbimed Advisors LLC boosted its holdings in shares of Corbus Pharmaceuticals by 8.8% in the 1st quarter. Orbimed Advisors LLC now owns 1,737,287 shares of the biopharmaceutical company’s stock valued at $16,313,000 after purchasing an additional 140,000 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Corbus Pharmaceuticals by 76.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 136,602 shares of the biopharmaceutical company’s stock valued at $1,281,000 after buying an additional 59,248 shares during the period. Exome Asset Management LLC grew its stake in shares of Corbus Pharmaceuticals by 67.8% during the 1st quarter. Exome Asset Management LLC now owns 234,136 shares of the biopharmaceutical company’s stock valued at $2,199,000 after buying an additional 94,593 shares during the period. Ieq Capital LLC acquired a new stake in shares of Corbus Pharmaceuticals during the 3rd quarter worth $96,000. Finally, Engineers Gate Manager LP increased its holdings in shares of Corbus Pharmaceuticals by 109.9% during the 2nd quarter. Engineers Gate Manager LP now owns 29,800 shares of the biopharmaceutical company’s stock worth $280,000 after buying an additional 15,600 shares during the last quarter. Institutional investors and hedge funds own 64.64% of the company’s stock.

Insider Activity

In related news, major shareholder Cormorant Asset Management, Lp sold 425,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $4.10, for a total value of $1,742,500.00. Following the sale, the insider directly owned 1,919,971 shares of the company’s stock, valued at approximately $7,871,881.10. This trade represents a 18.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 3.50% of the company’s stock.

Trending Headlines about Corbus Pharmaceuticals

Here are a few of the latest headlines about CRBP:

  • Positive Sentiment: HC Wainwright maintained its Buy rating and $35 price target, while raising its 2027 and 2028 EPS estimates to reflect somewhat smaller projected losses. MarketBeat analyst estimates
  • Negative Sentiment: HC Wainwright cut its Q4 2026 and full-year 2026 EPS forecasts, and reduced estimates for 2029 and 2030; its revised projections continue to show losses. The lowered outlook may reinforce concerns about the company’s path to profitability. MarketBeat analyst estimates
  • Negative Sentiment: As additional context, Corbus reported a quarterly loss of $1.81 per share, worse than analysts’ expected loss of $1.27 per share, which could add pressure alongside the estimate cuts.

About Corbus Pharmaceuticals

(Get Free Report)

Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical company focused on developing medicines for serious diseases in oncology and immunology. The company’s research is centered on therapies designed to modulate immune-cell activity and target biological pathways involved in cancer and inflammatory disease. Corbus’ oncology pipeline has included soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) being evaluated for its potential to treat T-cell lymphomas and other cancers.

Featured Stories

Earnings History and Estimates for Corbus Pharmaceuticals (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.